Cspc Pharmaceutical Group Limited · HKEX:1093
Cspc Pharmaceutical — FY2025 Earnings Presentation
30 slides from Cspc Pharmaceutical's earnings presentation, March 2026
Slide 1: CSPC Pharmaceutical Group Limited 2025 Annual Results
1528 6Ro0 CSPC CSPC PHARMACEUTICAL GROUP LIMITED (Stock Code : 1093) 20252 Fee iat et 202643F
Slide 2: 2025 business highlights
Lm 2025 wesseh Mi tanith BR (BAAVENTE) SR: BEE + REPS. SSERE + SBR -1LBERE + SMB PILEAR TRSRHRIEITIE: + SYS6010 (EGFRADC) - NSCLC + ERs) (ASAAAH) -PEComa + GRRE (ISKNOO3) - INE + JMT101- Ea + GRAB USKNOO3) - ABs WINER sess mas, semtZOZ I zen 202seeeitHein IZ BG (27 B tz 16 ANINDEGEF: | + AEIS8 | 4bs
Slide 3: Business development deals
Lm BDA(HRMSS — 2025S TSM AT INET, = syste = BX fa SP) eit mpemae9 7.1 zser, HpeRAt2 CET @rasicsen PISERRA RI RES ESERIES 6] BABYANSE Cipla astrazeneca iz SYS6005 / ROR1 ADC SALLE RA EAS KASUMI ACE JSON A] A PEL, SEL HSOM/ET] ROAR RIL, Batak: 1500753670 Bitter: 15005887 He: 121236 BBR: 12.25/23 BTR:
Slide 4: Key pipeline progress 2025
Ley iRSHAAY (2025) ithe - IR “RE” -ErbrHisA (14) JMT106 SYS6040 SYS6036 SYS6043 BPR (ABASSY) REVS (KNO26) BRRERAT RERe (aR GPC3/IEN Wi © DLL3 ADC eB B7H3 ADC TLHR+HER2- SLA HER2 + FaRSSMATT (JSKNO03) (KNO26) SL esd LIME NE SCLOSR HEHE HER2(E FE FBR 2L HER2+ i HER2+3L885 SYS6010 HERZ EGS 2L EGFRmut N
Slide 5: 2026 major conference presentations
Lm 2026%FetBisHitE! = CF) B/W CO seein SYS6010 SYS6043 SYS6043 >» © — sys6010 AACR EGFR ADC ICHNO B7H3 ADC Ref) B7H3 ADC trap EGFR ADC BIE eum A— plenary | SH ganage iy proffered | serpy geuae ag - 2L EGFRmut NSCLC oral presentation paper (LBA) scientific plenary HIB ————____/ oral presentation ————
Slide 6: Financial results
Msi
Slide 7: Financial results overview
a Le Msn= a Sqr: ARMED 20252 20245 sah WA, 26,006 29,009 -10.4% B= 17,059 20,299 -16.0% = SEs 65.6% 70.0% -4.4 pp REA 5,809 5,191 +11.9% AGAR ALR 3,882 4,328 -10.3% AQHURANASA 3,534 4,683 -24.5% SARA (ARS) + BFACRUREW ASI 33.98 36.87 -7.8% | HE: ASSURE) GESBUSIRESTHRMEIN) . HERDS tec Sate CARA | SCR
Slide 8: Results by segment
Le He Si: ARMA He mAAID HB EILA 2025¢F 2024¢¢ ah ) pS SSS Sd ee PEE 1 RES 20,584 23,736 -13.3% el eo SEE CRE 2,231 1,994 +11.9% ReEsRe 1,426 1,589 -10.2% WHARRHG| 1,765 1,690 +4.5% — PRS EIA 2025 | 2024% aah PERG 7,817 9,645 -19.0% ihe 2,201 4,400 -50.0% oe 3,324 4,086 -18.7% one 1,834 2,079 -11.8%
Slide 9: Segment profit and margins
Lm Sez =— Sir: ARE BIC 20255 20248 wal amare || SS Sal ees 3,871 4,828 -19.8% 18.8% 20.3% -1.5 pp BRC 192 211 -9.2% 8.6% 10.6% -2.0 pp nezReA 184 299 -38.4% 12.9% 18.8% -5.9 pp HeARRAS 276 305 -9.6% 15.6% 18.1% -2.5 pp (HE: AEA MTR 3S SUE 2A MER MH AS REA RTCA Ue. Bl, ST RAPLZSANE HRS SH | | A FLA R
Slide 10: R&D and pipeline
TREE
Slide 11: R&D strategy highlights
HAAURIAE » SAMAR HERE * A2OMENMAM EMMA + SREZERA TARR + 2S ERE SIS + 8A + 2666S Fl Ris + 10654 SFI MMA RR + BIRERARIMAEA + SAAR RD 11
Slide 12: R&D technology platforms
Le /\ATRRAES DAM RAEA > RECITES RIS > Sb (BSRSAB) > PITS RAS > APRs) (ARASAD) inh /M@ASARAES Set sakes isd > JMT203 (GFRAL) > JMT106 (GPC3/IFNa) > JMT206 (ACTRIIA/IIB) > SYS6090 (PD-1/IL-15) HE: S48 PIR AR TRE aa RARRES > HiwiaSmRNASS > VZV Rs SSeS > HPV ESAT HERE MT RALS > SYS6020 (BCMA CAR-T) >» S
Slide 13: 2026-2028 expected approvals and launches
Lom BAS eeiet Ua HA 2026-2028 it Linea | SN Y ent W Rare SBIR Ee BPIZaE® BBSER® (AIS) Bazsig® Bats Est tld FIBRO DANSE SI \ BzF® / SUSE PLE Samsin BlESIE Va BB BERR (KNO26) wFEREBH (Bit) HER2+ fe BEMAD BEA SAA ae SmCMheeR AALS EES THOROGAEER pee BREE oy) (BR) DBE (op users cpl TG103;¢537R SS 2027-20
Slide 14: JMT101 clinical data
Le JMT10125 ERR /SIACS RAR ini (3L+) BY REM). XSRR. FRRLAINEA CS JMT101 + irinotecan + SGOC ‘JMT101 + irinotecan (Arm B) -3.2 (20.3, 140) 10.2 (-12.1, 32.5) SURRLLLAHA: 20254418248 2025 ASCO (Arm A, n=36) (Arm B, n=35) (Arm C, n=35) Ra 18 20 28 n/N (%) (50.0) (57.1) (80.0) mPFS, 5.7 7A 2.9 Mo (95%Cl
Slide 15: HER2 ADC phase 3 data
Le SELASSIE RES + iy vs RH + ei TIaFHERZ+ Bee (24+) Ill RFR SER EAR Xx PFS: 7.1 vs 2.7 mo * OS: 19.6 vs 11.5 mo HR 0.25 HR 0.29 % ORR: 56% vs 11% %X Grade >3TRAEs 60% vs 45% IRC-assessed PFS: primary endpoint OS: co-primary endpoint Anbenitamat plus chemotherapy significantly reduced the risk of pro
Slide 16: Obesity programs data
Ce SI RIRBIBUEA TA ° THE. obesityweek | Os: JMT206 November 4-7, 2025 « Atlanta Best-In-Class ACTRIIA/IIB Blocker For Superior Body Composition Management In Combination With GLP-1 RAs ID; Poster-467 CSPC-ALK7— ALK7 E25) CCSPC-ALK7, 2 ALK7 siRNA Demonstrates Efficacy in Reducing Body Weight and Abdo
Slide 17: mRNA and CAR-T platform
— a [om HAC: - ER. CAR-T = —intiimRNABEF A SEB SR SIGPEARILNP Ex vivo CAR-T, BIA BSS IPRA IN vivo CAR-T >) mRNA RMS ere SEAR a Pat] seRIRA IER aR i BR = BASIS «FADER FIN a a EBR2° eee BYE CN a SYS6017 VZV mRNA Bo Napeat=a2) SYS6026 HPV mRNA JATreEREA «HPV 16/1824 KR aK ERAS Ex vivo CMA CAR-T SYS6020
Slide 18: siRNA platform
Ley SHAE - SIRNARDI CNS —————_@ FE LIVER enn 6 over st ADIPOSE MUSCLE _— IGS, SARS S RAM; PRASCUUIR. lib, GBBG. ALAC eis, RET ASME ESR oR Ei] IGGPRIEE IGRI IGGPRINRE Libris SYH2053 PCSK9 SIRNA AP IETEA SMES SYH2068 LP(a) SiRNA SYH2062 AGT SIRNA SIME SYH2070* — ANGPTL3 SIRNA MESS SYH2061* —¢5 SIRNA _
Slide 19: Pipeline - metabolic and respiratory
Loy BAe — Enea — Sexraalletc, OsrsaxBla, Teer FSseierRInE — Bains, Mmibiay, ADCSeHAwAt EB(RieGm Ea aw IGRI Gi PRIEA GRIER Lip RIS it RE area, L170 ceypewes «RIBS ESAS IL-4Ra EMM FSRAEBS SYS6093 (CM326) TSLP a CHES STOSOE (NHB) . (SREREESAEBSPS (IIIBB) . COPD (IIB) TG1033E8R GLP-1 ASA E-BLA, 22S RS (
Slide 20: Pipeline - oncology
= Lem Tees - EenAN — +E Et ES) IGPRIEE ISPRIR IGPRINIER rbHiS 6 JMT103 RANKL iL ibe bh: SSMiee; SYSA1802 PD-1 ai HLTH: RHA; RLS HER2 wa 2LSREBLA, 1L9LEREE (IIH) | FLEREERTISB (NHA) DBS HER2 FWA JMT101 EGFR Bi JPME . ABE SYS6036 RE SAEs SUE JMT203* GFRAL Bi Aaa a SYS6090* PD-1/IL-15 WHRERIASA RISC, R
Slide 21: Pipeline - NDA stage and others
Lom PRseeees - area Al — Asi arlt, SeukseNDA, S2cyhFseReIERMER —mHA. BSA. AKESSHa Dt SERA xB IGPRIBE IGPRINEE (GRP Lipa Lib ERC ORE RAE Ee NMPAi# Era: PTCL; 71 MOSD (II) PIR AES Been NMPAHE ETH: 1L/2LERIRE; FDARIL: 2LARBRE ESRB ABR Va NMPAIDEETS: RHReR; FDARHL: RBH RVBRBAAM (AB) * wea FRE Ls BPRS) (
Slide 22: Pipeline - CNS and others
| Lm RRES - harap = Texranilltt,, Tec8eNDA, OxeKhFHeIPRITER EER DRA Ee IGPRIEA WPRIEA IGPRINIEE Erb 16 SYHA1813 VEGFR/CSFIR ASF REBAR, SCLOIERATT ap SYH2043 CDK2/4/6 DBF ARE i SYH2045 PRMT5 NDF BBE Beye DPP-4 DBF 2HiyehRIs (SRL) . 2Biebees SABA (IIHR) NDA SE MeRr GABAA DBF Pret a bene haere SYHX1901
Slide 23: 2025-26 key milestones
ksird * ty a Ley SS25_bibite — wRit2025-26eE OO +m; saree 3 Om. 2025 2026 (sobme/éomy RARE SEMI MEA sOGREORH = RHEE wee me | miei Bite HRS ACS RR HRA SER SORRBEH aera Cee oe FUBDISBABREE sth wee VO ae BHC SHB ase nesta BBAUNEEH SRATATRREH err. | URIS Sine aii BSH i VA ae aSee asee tests ceria HAMTRE
Slide 24: ESG
ESG
Slide 25: ESG ratings and performance
Lg SIIB R ROW, MOF RAR ILESGRES = 20245F IM RABE MSCI ESG 242A SFiFRAA VA20175FHERR AE ene ene eee eee SVE MATS SRA AVENSERAYD A-A—A—A-A 153.0% 172.0% | 26.5% | ~ RARE PEATEUCAKE | a =< { 49.7% { 32.8% Sep-19 ‘Aug-20 Apr-21 Dec-21 Nov-22 Oct-23 Oct-24 Aug-25! © 202;BeAMZO-EREiUUC(‘<‘<‘“‘ OC!!!” ; _
Slide 26: Appendix
tS: BAR
Slide 27: Company overview
Cm PeesLeveresiun = We t°s4h — + 10+325 RE Bee Bx + SBIR 20008; YnslrIseeAe 250,000L BIS ta + (ESRB BIRISEPHELIZOO(ZE; (LeSTESTHIEAEHI3Z0(Zz PERSE + RSmRNABHRIMAET EI; E/E Eee p PeESL — ~200: + S94 10,000+A CES -° Eis 35,000+k, 25 350,000+% + 77EMO110+ Sa; EE BE BASS 27
Slide 28: Shareholder and dividend information
Lm PRESS irs oie aR ERR abe PERSE SuSE _ 41.59% 2025sHit: 187.95{Z mes (FAEELEMLA ) FRR Peg 17.69% hie 11.71% erate) thier Silat (Sarm: Are. BF? (MRARIUEBH) . + Ese an: PRA® (CiBIACHRE) . + ESE in: PSSAK® (RII BLA) . ' $2: & + ERP h: BOS? BSR (EBA INKSRE AiR) . SFR, BES (MSW RENR/A) . B® GRREHIERH)
Slide 29: Product approvals and launches
rr CURR: Baten ers) FeRAM MES 1 Pree 4 Be: > Wee zn? 7 SRR° Ta san Fa atte THERE £53 EAA TNK PEGI ABER BS RUBIA SRS TSS ARR AB Ra MAF ESR eae Ha ESTE ve it i. it = Vesa = A — ' = cad a | so EES | eres? Imag SaFI5° ae [- a6: SRBEARIEER ie SMRNARA Hf ES PAIES RBES EARLS Ee Ha ts RE RERES SY 04 - yl! -
Slide 30: Investor relations contact
AAR AIRAB MBA: ir@cspc.cn SUPPORT y RRB: oe ; GUIDANCE 7
CSPC Pharmaceutical Group — FY2025 Earnings Presentation on 6ix